The Food and Drug Administration granted accelerated approval to iberdomide, sold as Zenbexus, for adults with multiple myeloma who have received at least one prior line of treatment. The decision, announced on August 13, introduces the first drug in the class of cereblon E3 ligase modulators (CELMoDs) into myeloma care.
For patients weighing what comes after a first relapse, the practical significance is placement. This is not a last-resort option reserved for those who have exhausted all other options. It is approved for use as early as the second line of therapy, in a three-drug combination built around treatments myeloma patients and their oncologists already know.
